skip to main content

BRAF V600E NSCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateLung CancerBRAF V600E NSCLCSCE Medical Oncology

A 60-year-old man with NSCLC is found to have a BRAF V600E mutation (~2-4% of NSCLC adenocarcinoma). What targeted therapy is available?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Dabrafenib + trametinib (BRAF + MEK inhibitor combination) — ORR ~64% in previously treated and ~64% in treatment-naive BRAF V600E NSCLC; NICE approved

BRAF V600E NSCLC (~2-4%): dabrafenib + trametinib (NICE TA751) achieves ORR ~64%, median PFS ~14 months. Unlike CRC, dual BRAF+MEK inhibition works without anti-EGFR. Unlike melanoma, single-agent BRAF inhibition also has reasonable activity but combination is preferred.

Reference: NICE TA751; BRF113928; ESMO 2024 NSCLC